Meeting
2022 ASCO Genitourinary Cancers Symposium
The PRIMETEST trial: Prospective phase II trial of primary retroperitoneal lymph node dissection (RPLND) in stage II A/B patients with seminoma.
Authors
Peter Albers
Department of Urology, Heinrich-Heine-University, Düsseldorf, Germany
Peter Albers , Achim Lusch , Yue Che , Christian Arsov , Guenter Niegisch , Andreas Hiester
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT2015053664
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 420)
DOI
10.1200/JCO.2022.40.6_suppl.420
Abstract #
420
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
The PRIMETEST trial: Interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment.
First Author: Peter Albers
Poster
2023 ASCO Annual Meeting
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
First Author: A. Dimitrios Dimitrios Colevas
Poster
2023 ASCO Genitourinary Cancers Symposium
EDEN (Etude Désescalade sEmiNome): Prospective therapeutic de-escalation and miRNA-M371 biomarker evaluation phase II study for stage IIa/IIb < 3 cm seminomas.
First Author: Armelle Vinceneux